Navigation Links
Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010
Date:9/29/2010

Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010 -- WEIFANG, China, Sept. 29 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Food & Beverages, OTC, SmallCap, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Earnings Click to view news release full screen  

Shengtai Pharmaceutical Reports Financial Results for Full Year Fiscal 2010

 

WEIFANG, China, Sept. 29 /PRNewswire-Asia-FirstCall/ -- Shengtai Pharmaceutical, Inc. (OTC Bulletin Board: SGTI) ("Shengtai" or "the Company"), a manufacturer and distributor in China of glucose and starch as pharmaceutical raw materials and other starch and glucose products, today reported financial results for the twelve months ended June 30, 2010.

Full Year Fiscal 2010 Results

Sales revenue for the fiscal year ended June 30, 2010 was $115,953,948, an increase of $42,632,086, or 58% compared with the corresponding period in 2009. The increase in sales revenue resulted from the increase of the Company's sales volume and selling prices. Net sales from exports for the year ended June 30, 2010 increased approximately 131% compared with the same period in 2009. The increase is attributable to the recovery of the global economy. Domestic sales for cornstarch and other products for the year ended June 30, 2010 increased approximately 55% compared with the same period last year. The increase in domestic sales was attributable to the higher demand for the Company's products and increase in unit sales prices.

Costs of goods sold for the year ended June 30, 2010 was $98,276,190, an increase of $32,476,704, or 49% compared with the corresponding period in 2009. The increase in cost of sales was lower than the increase in net sales. As a result, the gross profit for the year ended June 30, 2010 was $17,677,759, an increase of $10,155,383, or 135%, compared with the same period in 2009, and the gross profit margin for the year ended June 30, 2010 was 15.2%, an increase from 5.0% for the same period in 2009.

Net profit for fiscal 2010 was $3,198,981 or 0.17 per share as compared to a net loss of $2,663,888 or $0.14 per share for fiscal 2009.

Net cash from operating activities for fiscal year 2010 was $9,578,970 compared to $1,287,385 from in operating activities for fiscal year 2009, an increase of $8,291,585.

Net cash used in investing activities for fiscal 2010 was $16,576,493 compared to $1,432,818 used in investing activities for fiscal year 2009. The investing activities helped the company increase its production capacity via purchase of equipments and optimization in production process.

Management Comments

Commenting on the operating and financial results, Qingtai Liu, CEO of Shengtai Pharmaceuticals stated, "We are continuing our global expansion and diversification strategies which are currently benefiting from strong market growth. During this past year we increased our production of pharmaceutical grade glucose products, in particular dextrose monohydrate. Dextrose monohydrate is one of the five most important medical prescriptions in the PRC and one of the most widely used pharmaceutical products for restorative and nutritional purposes. It is used as a raw material in a wide array of pharmaceutical products such as transfusions and intravenous drips. Our cornstarch production capacity has been enhanced to 300,000 tons a year."

Mr. Liu continued, "Our return to profitability is a combination of our cost controls, diversified product lines and numerous sales initiatives. Our glucose facility allows us to use self-produced cornstarch to produce glucose and to be able to ensure the adequacy and quality of the cornstarch we use. Since cornstarch is produced on our premises, we are able to eliminate costs to ship the cornstarch to our glucose production facility, thus resulting in lower manufacturing costs.

"We are currently applying new production technology to recycling of our waste water and byproducts. At the same time, we are improving overall production efficiency by analyzing and ameliorating inefficient production processes. Environment protection and production efficiency are important in our growth," concluded Mr. Liu.

A conference call to further discuss earnings will be held Thursday, September 30th at 8:00 A.M. Eastern Time.

To participate, please call the following numbers ten minutes before the call start time:

Phone Number + 1 (877) 407-8035 (North America) Phone Number + 1 (201) 689-8035 (International)

A replay of the call will be available through October 7, 2010, at 11:59 P.M. Eastern Standard Time. For the replay, please call:

Phone Number +1 (877) 660-6853 (North America) Phone Number +1 (201) 612-7415 (International) Account Number: 286 Conference ID Number: 357935

About Shengtai Pharmaceutical, Inc.

Shengtai Pharmaceutical, Inc. through its wholly owned subsidiary, Shengtai Holding, Inc. (SHI), and the Chinese operating company of Weifang Shengtai Pharmaceutical Co., Ltd., is a manufacturer and distributor in China of glucose and starch products as pharmaceutical raw materials, other starch products and other glucose products such as corn meals, food and beverage glucose and dextrin. For more information about Shengtai Pharmaceutical, Inc., please visit http://www.shengtaipharmaceutical.com .

Forward Looking Statements

Certain statements in this press release and oral statements made by the Company constitute forward-looking statements concerning the Company's business and products. These statements include, without limitation, statements regarding our ability to prepare the Company for growth, the Company's planned capacity expansion and predictions and guidance relating to the Company's future financial performance. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs, but they involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand especially in the pharmaceutical industry, pricing and demand trends for the Company's products, changes to government regulations, risk associated with operation of the Company's new facilities, risk associated with large-scale implementation of the Company's business plan, the ability to attract new customers, ability to increase its product's applications, cost of raw materials, downturns in the Chinese economy, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. Investors are urged to consider these factors carefully in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations.

For more information, please contact: Shengtai Pharmaceutical, Inc. Mr. Hu Ye Chief Financial Officer Tel: +86-139-1157-3505 Email: shengtaicfo@hotmail.com Shengtai Pharmaceutical, Inc. Ms. Cherry Shuzhen Ge Investor Relations Manager Tel: +86-0536-6295802 Email: shengtaigsz@hotmail.com Investor Relations DME Capital LLC David Elias Tel: +1-516-967-0205 Email: dave@dmecapital.com
'/>"/>

SOURCE Shengtai Pharmaceutical, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Weifang Shengtai Purchased MVR Evaporator for Energy and Cost Saving
2. Shengtai Pharmaceutical, Inc. Reports Financial Results for the Third Quarter and the First Nine Months of Fiscal Year 2010
3. Shengtai Pharmaceutical, Inc Announces Appointment of New Chief Financial Officer
4. Prolong Pharmaceuticals Names Industry Veteran Glenn Kazo President
5. Tigris Pharmaceuticals, Inc. Completes $6.5 Million Private Placement
6. Tigris Pharmaceuticals Appoints Neil Flanzraich to Executive Chairman of the Board
7. Endo Pharmaceuticals Announces Agreement to Acquire Qualitest Pharmaceuticals for $1.2 Billion
8. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
9. Amira Pharmaceuticals Announces IND Submission for Novel LPA1 Antagonist, AM152, for Potential Use in Fibrotic Diseases
10. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2010 Earnings Conference Call on Thursday, September 30, 2010 at 9:00 a.m. ET
11. China BCT Further Expands its Footprint by Acquiring 33 Retail Pharmaceutical Stores
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016   HighPoint ... November Research Group (NRG),s pharmacovigilance technology services division.  ... consulting services and an Oracle Argus Specialized partner, ... to Life Sciences companies. --> ... expands HighPoint,s life sciences capabilities and provides a ...
(Date:2/8/2016)... PALO ALTO, Calif. , Feb. 8, 2016 ... and Kodiak Sciences Inc., a biopharmaceutical company designing and ... announced today agreements for the clinical supply of Kodiak,s ... at multiple sites, including Slough (UK), Visp (CH) and ... --> Retinal diseases, such as age-related macular degeneration ...
(Date:2/8/2016)... , Feb. 8, 2016  Avista Pharma Solutions ("Avista ... Setzer as Chief Financial Officer (CFO). Mr. Setzer is ... of experience in various roles within growing technology and ... served as the Executive Director of Finance at INC ... Raleigh, NC . Previously, Mr. Setzer served ...
Breaking Medicine Technology:
(Date:2/8/2016)... Encinitas, CA (PRWEB) , ... February 08, 2016 ... ... study showing greater than 50% lower incidence rate of type 2 diabetes in ... national averages. ”It is time to make a change in public health,” states ...
(Date:2/8/2016)... , ... February 08, 2016 , ... TopConsumerReviews.com recently awarded ... Mole removal products. , Moles are derived from a cluster of melanin when exposed ... the wrong places and create a lifetime of embarrassment. Historically, mole removal ...
(Date:2/8/2016)... ... February 08, 2016 , ... Guruji Mahendra Kumar Trivedi is offering ... 2016 in honor of his birthday on February 10th. During this time, people ... is known by over 250,000 people from over 40 different countries as an “ordinary ...
(Date:2/8/2016)... ... 08, 2016 , ... According to research by the National ... technicians to be certified or obtain continuing education. To increase patient awareness of ... Your Mouth?” campaign to inform dentists and patients about the possible lack of ...
(Date:2/7/2016)... (PRWEB) , ... February 07, 2016 , ... Women's Excellence ... National Wear Red Day. National Wear Red Day is the first Friday each ... Heart disease and stroke cause 1 in 3 deaths among women each year – ...
Breaking Medicine News(10 mins):